NASDAQ:IMTX

Immatics Biotechnologies Gmbh Stock Insider Trading

Healthcare > Biotechnology

Buy IMTX

*Your capital is at risk

$10.21

+0.165 (+1.64%)

At Close: Jun 03, 2026

immatics biotechnologies GmbH Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 11.33M and sold 0 IMTX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	11.33M shares
● Sell	0 shares
100% Buy Activity Weak Negative Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 18, 2026 Buy	Ordinary Shares	Reinhardt Carsten Alexander Johannes Chief Development Officer	Officer	0 Value: $0
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Reinhardt Carsten Alexander Johannes Chief Development Officer	Officer	18 753 Value: $19.9K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Reinhardt Carsten Alexander Johannes Chief Development Officer	Officer	255 000 Value: $2.55M
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Reinhardt Carsten Alexander Johannes Chief Development Officer	Officer	49 000 Value: $474.3K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Reinhardt Carsten Alexander Johannes Chief Development Officer	Officer	98 000 Value: $1.08M
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Reinhardt Carsten Alexander Johannes Chief Development Officer	Officer	90 000 Value: $877.5K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Reinhardt Carsten Alexander Johannes Chief Development Officer	Officer	92 000 Value: $833.5K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Reinhardt Carsten Alexander Johannes Chief Development Officer	Officer	88 000 Value: $709.3K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Reinhardt Carsten Alexander Johannes Chief Development Officer	Officer	160 000 Value: $1.49M
Mar 18, 2026 Buy	Restricted Stock Units	Reinhardt Carsten Alexander Johannes Chief Development Officer	Officer	40 000 Value: $387.2K
Mar 18, 2026 Buy	Ordinary Shares	Britten Cedrik Michael Chief Medical Officer	Officer	0 Value: $0
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Britten Cedrik Michael Chief Medical Officer	Officer	255 000 Value: $2.55M
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Britten Cedrik Michael Chief Medical Officer	Officer	49 000 Value: $474.3K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Britten Cedrik Michael Chief Medical Officer	Officer	98 000 Value: $1.08M
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Britten Cedrik Michael Chief Medical Officer	Officer	112 500 Value: $1.10M
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Britten Cedrik Michael Chief Medical Officer	Officer	155 000 Value: $1.40M
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Britten Cedrik Michael Chief Medical Officer	Officer	150 000 Value: $1.21M
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Britten Cedrik Michael Chief Medical Officer	Officer	200 000 Value: $1.86M
Mar 18, 2026 Buy	Restricted Stock Units	Britten Cedrik Michael Chief Medical Officer	Officer	50 000 Value: $484.0K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Sturchio Edward A Jr General Counsel	Officer	36 000 Value: $360.0K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Sturchio Edward A Jr General Counsel	Officer	30 000 Value: $290.4K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Sturchio Edward A Jr General Counsel	Officer	30 000 Value: $387.6K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Sturchio Edward A Jr General Counsel	Officer	30 000 Value: $330.0K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Sturchio Edward A Jr General Counsel	Officer	60 000 Value: $585.0K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Sturchio Edward A Jr General Counsel	Officer	52 500 Value: $623.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT IMMATICS BIOTECHNOLOGIES GMBH

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I ...

Read Full Profile Here